+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada



The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada



Bulletin du Cancer 93(9): 841-846



The unique genetic demography of the French Canadian population of Quebec, Canada, has provided a means to study the contribution of BRCA1 and BRCA2, the breast-ovarian cancer susceptibility genes. Here we review BRCA1 and BRCA2 in the context of French Canadian cancer families, a well-characterized founder population known for its contributions to medical genetics. Pathogenic BRCA1 and BRCA2 mutations contribute to a significant proportion of hereditary breast and/or ovarian cancer families of French Canadian descent. BRCA1 and BRCA2 mutations have been reported in approximately 40 % of families with at least three cases of breast and/or ovarian cancer, where breast cancer diagnosis occurred before age 66 years, and where all cases occurred within first-, second- and/or third-degree relatives to index affected cases tested for mutations. The proportion of mutation-positive families was very similar to that reported in independent studies of families not selected for ethnicity. However, 84 % of mutation-positive families were accounted for by one of eight pathogenic mutations in BRCA1 (2953delGTA + C, 3875delGTCT, and 4446C --> T) and BRCA2 (2816insA, 3398delAAAAG, 6085G --> T, 6503delTT, and 8765delAG). Haplotype analyses has suggested that carriers of the most common recurring mutations share a related ancestry. This effect has been attributed to common founders in the French Canadian population of Quebec who emigrated from France in between 1608 and 1759. It is possible that novel highly penetrant cancer susceptibility genes account for a fraction of the 60 % of BRCA mutation-negative French Canadian cancer families. The continued genetic analysis and phenotypic characterization of French Canadian cancer families is warranted given the large family structure of these families are amenable for classical genome-wide linkage analysis for novel breast and ovarian cancer susceptibility genes.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050665002

Download citation: RISBibTeXText

PMID: 16980226


Related references

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics 63(5): 1341-1351, 1998

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population. Hereditary Cancer in Clinical Practice 16: 12, 2018

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncology Letters 9(6): 2787-2790, 2015

Common BRCA1 and BRCA2 mutations in hereditary breast-ovarian cancer families of French-Canadian population. Proceedings of the American Association for Cancer Research Annual Meeting 39: 475, 1998

Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. International Journal of Cancer 112(3): 411-419, 2004

Molecular epidemiology of BRCA1 and BRCA2 mutations in high risk French Canadian breast/ovarian cancer families. European Journal of Human Genetics 9(Supplement 1): P0080, 2001

Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer. Clinical Genetics 59(6): 418-423, 2001

Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Human Mutation 15(5): 480-481, 2000

Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families. Journal of Clinical Oncology 26(15_suppl): 22108-22108, 2016

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2): 97-102, 2006

Prevalence of founder BRCA1 and BRCA2 mutations in French Canadian women with breast cancer unselected for age or family history. American Journal of Human Genetics 67(4 Supplement 2): 85, 2000

Low proportion of BRCA1 and BRCA2 mutations in French Canadian breast cancer families. American Journal of Human Genetics 65(4): A323, 1999

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Journal of Medical Genetics 39(8): 611-614, 2002

Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. International Journal of Cancer 95(3): 189-193, 2001

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics 60(5): 1059-1067, 1997